{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:30:52Z","timestamp":1794576652304,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"DOI":"10.1186\/s40644-026-01036-6","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:37:53Z","timestamp":1777563473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic value of PSMA PET\u2013derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide"],"prefix":"10.1186","volume":"26","author":[{"given":"Tugay","family":"Atasever","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunduzalp Bugrahan","family":"Babacan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer Burak","family":"Ekinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asl\u0131","family":"Buyukkuscu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyza Soylu","family":"Uslu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Zehra Y\u0131ld\u0131z","family":"Kabaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Mustafa","family":"Atc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sava\u015f","family":"Karyagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Ert\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"\u00c7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"6","key":"1036_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.2149","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.2149.","journal-title":"CA Cancer J Clin"},{"key":"1036_CR2","doi-asserted-by":"publisher","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021. https:\/\/doi.org\/10.1002\/ijc.33588. Epub ahead of print. PMID: 33818764.","DOI":"10.1002\/ijc.33588"},{"key":"1036_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1885","author":"GK Panigrahi","year":"2019","unstructured":"Panigrahi GK, Praharaj PP, Kittaka H, Mridha AR, Black OM, Singh R, Mercer R, et al. Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. Cancer Med. 2019. https:\/\/doi.org\/10.1002\/cam4.1885.","journal-title":"Cancer Med"},{"key":"1036_CR4","doi-asserted-by":"publisher","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972 Jul-Aug;22(4):232\u2009\u2013\u200940. https:\/\/doi.org\/10.3322\/canjclin.22.4.232. PMID: 4625049.","DOI":"10.3322\/canjclin.22.4.232"},{"issue":"2","key":"1036_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1210\/jcem-68-2-461","volume":"68","author":"G Forti","year":"1989","unstructured":"Forti G, Salerno R, Moneti G, et al. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: Effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. J Clin Endocrinol Metab. 1989;68(2):461\u20138. https:\/\/doi.org\/10.1210\/jcem-68-2-461.","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"1036_CR6","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1158\/1078-0432.CCR-04-0913","volume":"10","author":"T Nishiyama","year":"2004","unstructured":"Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res. 2004;10(21):7121\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0913.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1036_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1365-2265.1987.tb00771.x","volume":"26","author":"J Geller","year":"1987","unstructured":"Geller J, Liu J, Albert J, et al. Relationship between human prostatic epithelial cell protein synthesis and tissue dihydrotestosterone level. Clin Endocrinol (Oxf). 1987;26(2):155\u201361. https:\/\/doi.org\/10.1111\/j.1365-2265.1987.tb00771.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1036_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1677\/erc.1.00525","volume":"11","author":"HI Scher","year":"2004","unstructured":"Scher HI, Buchanan G, Gerald W, et al. Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004;11(3):459\u201376. https:\/\/doi.org\/10.1677\/erc.1.00525.","journal-title":"Endocr Relat Cancer"},{"key":"1036_CR9","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1036_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.3390\/cancers12061367","volume":"12","author":"W Jones","year":"2020","unstructured":"Jones W, Griffiths K, Barata PC, Paller CJ. PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. Cancers (Basel). 2020;12(6):1367. https:\/\/doi.org\/10.3390\/cancers12061367. PMID: 32466595; PMCID: PMC7352725.","journal-title":"Cancers (Basel)"},{"issue":"10231","key":"1036_CR11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG, proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7. Epub 2020 Mar 22. PMID: 32209449.","journal-title":"Lancet"},{"issue":"16","key":"1036_CR12","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.3390\/cancers13163967","volume":"13","author":"M El Fakiri","year":"2021","unstructured":"El Fakiri M, Geis NM, Ayada N, Eder M, Eder AC. PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives. Cancers (Basel). 2021;13(16):3967. https:\/\/doi.org\/10.3390\/cancers13163967. PMID: 34439121; PMCID: PMC8393521.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"1036_CR13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/RLU.0000000000004763","volume":"48","author":"QA Shagera","year":"2023","unstructured":"Shagera QA, Karfis I, Sideris S, Guiot T, Woff E, Martinez-Chanza N, Roumeguere T, Gil T, Flamen P, Artigas C. Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel. Clin Nucl Med. 2023;48(9):775\u201380. Epub 2023 Jun 29. PMID: 37385221.","journal-title":"Clin Nucl Med"},{"issue":"17","key":"1036_CR14","doi-asserted-by":"publisher","first-page":"8143","DOI":"10.7150\/thno.60222","volume":"11","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weckesser M, Kersting D, Seitzer KE, Weber M, B\u00f6gemann M, Rahbar K. Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy. Theranostics. 2021;11(17):8143\u201351. https:\/\/doi.org\/10.7150\/thno.60222. PMID: 34373733; PMCID: PMC8344008.","journal-title":"Theranostics"},{"issue":"9","key":"1036_CR15","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","volume":"60","author":"A Gafita","year":"2019","unstructured":"Gafita A, Bieth M, Kr\u00f6nke M, Tetteh G, Navarro F, Wang H, G\u00fcnther E, Menze B, Weber WA, Eiber M, qPSMA. Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET\/CT. J Nucl Med. 2019;60(9):1277\u201383. Epub 2019 Mar 8. PMID: 30850484; PMCID: PMC6735278.","journal-title":"J Nucl Med"},{"issue":"1","key":"1036_CR16","doi-asserted-by":"publisher","first-page":"e222148","DOI":"10.1148\/radiol.222148","volume":"308","author":"A Gafita","year":"2023","unstructured":"Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Calais J, Rettig M, Eiber M, Weber M, Benz MR, Farolfi A. Response Evaluation Criteria in PSMA PET\/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology. 2023;308(1):e222148. https:\/\/doi.org\/10.1148\/radiol.222148. PMID: 37432081; PMCID: PMC10374938.","journal-title":"Radiology"},{"issue":"5","key":"1036_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A, Morris MJ, Fanti S, Weber WA, Hope TA, Hofman MS, Fendler WP, Eiber M. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023;83(5):405\u201312. Epub 2023 Mar 17. PMID: 36935345.","journal-title":"Eur Urol"},{"key":"1036_CR18","doi-asserted-by":"publisher","unstructured":"Beintner-Skawran S, Gafita A, Lorenzini T, Tauber R, Hober\u00fcck S, Mattana F, Di Giorgio A, Miederer M, Paller CJ, Djaileb L, Solnes LB, Farolfi A, Ceci F, Eiber M, Voter AF. [68Ga]Ga-PSMA-11 PET tumor volume predicts overall survival of patients with metastatic prostate cancer undergoing taxane-based chemotherapy. J Nucl Med. 2025 Sep;11:jnumed125269584. https:\/\/doi.org\/10.2967\/jnumed.125.269584. Epub ahead of print. PMID: 40935613.","DOI":"10.2967\/jnumed.125.269584"},{"key":"1036_CR19","doi-asserted-by":"publisher","unstructured":"Shagera QA, Karfis I, Kristanto P, Spyridon S, Diamand R, Santapau A, Peltier A, Roumegu\u00e8re T, Flamen P, Artigas C. PSMA PET\/CT for response assessment and overall survival prediction in patients with metastatic castration-resistant prostate cancer treated with androgen receptor pathway inhibitors. J Nucl Med. 2023;64(12):1869\u20131875. https:\/\/doi.org\/10.2967\/jnumed.123.265874. PMID: 37770114.","DOI":"10.2967\/jnumed.123.265874"},{"key":"1036_CR20","doi-asserted-by":"publisher","unstructured":"Giunta EF, Caroli P, Scarpi E, Altavilla A, Rossetti V, Marini I, Celli M, Casadei C, Lolli C, Schepisi G, Bleve S, Brighi N, Cursano MC, Paganelli G, Matteucci F, De Giorgi U. Correlation of [68Ga]Ga-PSMA PET\/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients. Eur J Nucl Med Mol Imaging. 2024;52(1):326\u2013334. https:\/\/doi.org\/10.1007\/s00259-024-06887-4. Epub 2024 Aug 29. PMID: 39207484; PMCID: PMC11599341.","DOI":"10.1007\/s00259-024-06887-4"},{"key":"1036_CR21","doi-asserted-by":"publisher","unstructured":"Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, Fendler WP, Hadaschik B, Kleesiek J, Sch\u00e4fers M, Weckesser M, Boegemann M, Rahbar K. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48(4):1200\u20131210. https:\/\/doi.org\/10.1007\/s00259-020-05040-1. Epub 2020 Sep 24. PMID: 32970216; PMCID: PMC8041668.","DOI":"10.1007\/s00259-020-05040-1"},{"key":"1036_CR22","doi-asserted-by":"publisher","unstructured":"Zang S, Meng Q, Li X, Guo T, Zhang L, Zhao Z, Yu F, Zhang P, Wu W, Ni Y, Shi Y, Shao G, Feng Y, Hu L, Jia R, Civelek AC, Guo H, Wang F. Fully automated volumetric assessment of tumor burden using artificial intelligence on 68Ga-PSMA-11 PET predicts survival after 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2026;53(3):1913\u20131926. https:\/\/doi.org\/10.1007\/s00259-025-07628-x. Epub 2025 Oct 20. PMID: 41111086.","DOI":"10.1007\/s00259-025-07628-x"},{"issue":"7","key":"1036_CR23","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1007\/s00330-025-11360-3","volume":"35","author":"Role of","year":"2025","unstructured":"Role of baseline ^68Ga\u2013PSMA PET\/CT\u2013derived whole\u2013body volumetric parameters in predicting survival outcomes of metastatic castration\u2013resistant prostate cancer patients receiving first\u2013line treatment. Eur Radiol. 2025;35(7):4223\u201332.","journal-title":"Eur Radiol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01036-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01036-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01036-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:02:39Z","timestamp":1781809359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01036-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1036"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01036-6","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed and approved by Prof. Dr. Cemil Ta\u015fc\u0131o\u011flu City Hospital Ethics Committee and conducted following the Helsinki Declaration and ethical principles (Approval date: 22 December 2025; approval number: 2025\/405). Due to the retrospective nature of the study, the requirement for written informed consent was waived by the ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}